JP2009510133A5 - - Google Patents

Download PDF

Info

Publication number
JP2009510133A5
JP2009510133A5 JP2008533836A JP2008533836A JP2009510133A5 JP 2009510133 A5 JP2009510133 A5 JP 2009510133A5 JP 2008533836 A JP2008533836 A JP 2008533836A JP 2008533836 A JP2008533836 A JP 2008533836A JP 2009510133 A5 JP2009510133 A5 JP 2009510133A5
Authority
JP
Japan
Prior art keywords
composition
composition according
epitope
antigen
liposome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008533836A
Other languages
English (en)
Japanese (ja)
Other versions
JP5528703B2 (ja
JP2009510133A (ja
Filing date
Publication date
Priority claimed from CA002523032A external-priority patent/CA2523032A1/en
Application filed filed Critical
Publication of JP2009510133A publication Critical patent/JP2009510133A/ja
Publication of JP2009510133A5 publication Critical patent/JP2009510133A5/ja
Application granted granted Critical
Publication of JP5528703B2 publication Critical patent/JP5528703B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008533836A 2005-10-07 2006-10-05 がん治療のためのビヒクルとして連続的疎水性相を含む担体におけるリポソームの使用 Expired - Fee Related JP5528703B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CA2,523,032 2005-10-07
CA002523032A CA2523032A1 (en) 2005-10-07 2005-10-07 Vaccines for cancer therapy
CA002533705A CA2533705A1 (en) 2005-10-07 2006-01-13 Use of liposomes in a water-in-oil emulsion or in a continuous hydrophobic carrier as a vehicle for cancer treatment
CA2,533,705 2006-01-13
CA002542212A CA2542212A1 (en) 2005-10-07 2006-04-07 Use of liposomes in a water-in-oil emulsion or in a continuous hydrophobic carrier as a vehicle for cancer treatment
CA2,542,212 2006-04-07
US80657306P 2006-07-05 2006-07-05
US60/806,573 2006-07-05
PCT/CA2006/001640 WO2007041832A1 (en) 2005-10-07 2006-10-05 Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment

Publications (3)

Publication Number Publication Date
JP2009510133A JP2009510133A (ja) 2009-03-12
JP2009510133A5 true JP2009510133A5 (enExample) 2009-11-26
JP5528703B2 JP5528703B2 (ja) 2014-06-25

Family

ID=37942250

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008533836A Expired - Fee Related JP5528703B2 (ja) 2005-10-07 2006-10-05 がん治療のためのビヒクルとして連続的疎水性相を含む担体におけるリポソームの使用

Country Status (8)

Country Link
US (3) US20090297593A1 (enExample)
EP (1) EP1948225B1 (enExample)
JP (1) JP5528703B2 (enExample)
CN (1) CN101282742B (enExample)
AU (1) AU2006301891B2 (enExample)
CA (4) CA2523032A1 (enExample)
ES (1) ES2451599T3 (enExample)
WO (1) WO2007041832A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2428103C (en) * 2000-11-07 2015-06-09 Immunovaccine Technologies Inc. Vaccines with enhanced immune response and methods for their preparation
US9090673B2 (en) * 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
JP5731198B2 (ja) * 2007-09-27 2015-06-10 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用
CN101815529B (zh) * 2007-10-03 2016-03-09 免疫疫苗技术有限公司 包含抗原、两性化合物和疏水载体的组合物及其应用
CN102056622B (zh) * 2008-06-05 2016-04-06 免疫疫苗技术有限公司 包含脂质体、抗原、多核苷酸和含疏水物质的连续相的载体的组合物
EP2755679B1 (en) * 2011-09-13 2017-08-02 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
CN113876945A (zh) * 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
EP2762158A1 (en) * 2013-02-05 2014-08-06 Nitto Denko Corporation E75-vaccine composition for transdermal administration
EP2978450B1 (en) 2013-03-27 2018-09-19 ImmunoVaccine Technologies Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer
AU2015283612A1 (en) * 2014-07-02 2017-01-12 Valeria CAGNO Oxysterols for use in the treatment and prevention of diseases caused by viruses
CN106573043A (zh) * 2014-08-04 2017-04-19 日东电工株式会社 抑制ctl的凋亡或阻断ctl的诱导抑制的疫苗药物组合物
CN107531736B (zh) 2015-01-06 2022-04-15 免疫疫苗科技公司 脂质a模拟物、其制备方法和用途
JP6851983B2 (ja) * 2015-05-01 2021-03-31 イミューノヴァクシーン テクノロジーズ インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． デポー形成及びデポー非形成ワクチンを使用して免疫応答を強化する方法
CA3005127C (en) 2015-11-18 2023-01-24 Immunovaccine Technologies Inc. Adjuvanting systems and water-free vaccine compositions comprising a polyi:c polynucleotide adjuvant and a lipid-based adjuvant
US11260116B2 (en) 2016-05-04 2022-03-01 Immunovaccine Technologies Inc. Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereof
US11505591B2 (en) 2016-05-18 2022-11-22 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CN109982715A (zh) * 2016-09-27 2019-07-05 免疫疫苗技术有限公司 利用低剂量体积b细胞表位组合物以在受试人中诱导抗体免疫应答的方法
KR102760578B1 (ko) * 2016-12-22 2025-02-03 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
IL269000B2 (en) 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
EP3768242A4 (en) * 2018-03-20 2021-12-08 ImmunoVaccine Technologies Inc. METHODS AND COMPOSITIONS FOR THE TARGETED DELIVERY OF ACTIVE SUBSTANCES AND IMMUNMODULATORY AGENTS TO LYMPH NODES
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
EP4211149A4 (en) 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
CN116531498A (zh) * 2023-04-11 2023-08-04 金宇保灵生物药品有限公司 一种免疫增强剂、制备方法及其应用

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5897873A (en) * 1984-04-12 1999-04-27 The Liposome Company, Inc. Affinity associated vaccine
US6093406A (en) * 1988-06-02 2000-07-25 The United States Of America As Represented By The Secretary Of The Army Vaccine for induction of immunity to malaria
FR2649013B1 (fr) * 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
US5015476A (en) * 1989-08-11 1991-05-14 Paravax, Inc. Immunization implant and method
IE904098A1 (en) * 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
US5709879A (en) * 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
AU654824B2 (en) 1990-06-29 1994-11-24 Chiron Corporation Vaccine compositions containing liposomes
KR100252371B1 (ko) * 1990-12-12 2000-05-01 포터 더글라스 서브유니트 파필로마비루스 백신 및 그들에 사용하기 위한 펩티드
CA2072249C (en) * 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
USRE37224E1 (en) * 1992-06-05 2001-06-12 Dalhousie University Method to prevent fertilization in mammals by administering a single dose of zona pellucida derived antigens, liposome and adjuvant
CA2137363C (en) 1992-06-05 1999-06-15 Robert Brown Use of zona pellucida glycoproteins for immunocontraception
US5736141A (en) * 1992-06-05 1998-04-07 Dalhousie University Method to prevent fertilization in mammals by administering a single dose of zona pellucida derived antigens, liposome and Freund's adjuvant
US5820879A (en) * 1993-02-12 1998-10-13 Access Pharmaceuticals, Inc. Method of delivering a lipid-coated condensed-phase microparticle composition
JPH06247842A (ja) * 1993-02-23 1994-09-06 Green Cross Corp:The リポソーム組成物の製造方法
JPH09502086A (ja) * 1993-08-06 1997-03-04 サイテル コーポレイション 完全ｍａｇｅ１遺伝子のクローニング及び特性決定
US20050049197A1 (en) * 1993-09-14 2005-03-03 Epimmune Inc. Induction of immune response against desired determinants
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
EP0759941B1 (en) * 1994-05-18 2000-09-13 S.P.I. Synthetic Peptides Incorporated Heterodimer polypeptideimmunogen carrier composition and method for their use
US5637300A (en) * 1994-08-03 1997-06-10 Dunbar; Bonnie S. Contraceptive vaccine comprising a glycosylated 55 kD zona pellucida protein immunogen and method of use of the same in contraception
US6355256B1 (en) * 1994-09-30 2002-03-12 Ludwig Institute For Cancer Research Compositions containing a p53 derived protein or peptide, an adjuvant, and interleukin-12 and uses thereof
US5705151A (en) * 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
US6168804B1 (en) * 1995-06-07 2001-01-02 University Of Alberta Method for eliciting Th1-specific immune response
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US6096313A (en) * 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US7019112B1 (en) * 1996-03-19 2006-03-28 University Of Virginia Patent Foundation Peptides recognized by melanoma-specific A1-, A2- and A3-restricted cytoxic lymphocytes, and uses therefor
US5919480A (en) * 1996-06-24 1999-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method
US5910306A (en) * 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6110492A (en) * 1997-05-28 2000-08-29 Jenner Biotherapies, Inc. Immunogenic compositions
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
JP2001513982A (ja) * 1997-08-29 2001-09-11 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド フォリスタチン−３
US6291430B1 (en) * 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6183746B1 (en) * 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6218371B1 (en) * 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6588671B2 (en) * 1998-04-09 2003-07-08 Dcard, Inc. Positioning of a recording head for a data storage device
US6472375B1 (en) * 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
GB9810236D0 (en) * 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6406719B1 (en) * 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
IL139700A (en) * 1998-06-15 2005-09-25 Altarex Medical Corp Immunotherapeutic composition for the treatment of prostate cancer
WO2000000178A1 (en) * 1998-06-30 2000-01-06 Rohto Pharmaceutical Co., Ltd. Compositions containing liposomes and/or emulsions and process for the preparation thereof
US20050084524A1 (en) * 1998-09-30 2005-04-21 Alza Corporation Method for potentiating activity of a chemotherapeutic drug
US6787154B2 (en) * 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
WO2000037100A2 (en) 1998-12-22 2000-06-29 Dalhousie University Compositions and methods for reducing or preventing fertilization in fish and birds
US6670195B1 (en) * 1999-05-26 2003-12-30 New York University Mutant genes in Familial British Dementia and Familial Danish Dementia
EP1221968B1 (en) * 1999-10-13 2010-01-13 Novartis Vaccines and Diagnostics, Inc. Method of obtaining cellular immune responses from proteins
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US6602510B1 (en) * 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
CA2428103C (en) 2000-11-07 2015-06-09 Immunovaccine Technologies Inc. Vaccines with enhanced immune response and methods for their preparation
AU1999802A (en) 2000-12-01 2002-06-11 Lawrence Boni Preparation of large liposomes by infusion into peg
ES2519043T3 (es) 2000-12-08 2014-11-06 Academisch Ziekenhuis Leiden Péptidos largos de 22-45 residuos de aminoácidos que inducen y/o mejoran las respuestas inmunológicas específicas para antígenos
CN1168740C (zh) * 2001-04-04 2004-09-29 上海美恩生物技术有限公司 细胞因子基因修饰的抗原提呈细胞/肿瘤细胞偶联物、其制法和用途
US20050037061A1 (en) * 2001-07-25 2005-02-17 Saiko Hosokawa Remedies for mammary cancer
WO2003011893A2 (en) * 2001-07-31 2003-02-13 University Of Washington Immunologically significant herpes simplex virus antigens and methods for using same
EP1474447A2 (en) 2002-02-08 2004-11-10 Immunovaccine Technologies Inc. Antigens for immunocontraception
US7056515B2 (en) * 2002-02-08 2006-06-06 Immunovaccine Technologies Inc. Antigens for immunocontraception
US20040101534A1 (en) * 2002-06-25 2004-05-27 Diamond Don J. Adjuvant-free peptide vaccine
JP2004051238A (ja) 2002-07-16 2004-02-19 Canon Inc シート搬送装置及び画像形成装置
US6586671B1 (en) 2002-08-06 2003-07-01 Interrail Signal, Inc. Above ground track signal terminal apparatus
WO2004017944A1 (en) * 2002-08-23 2004-03-04 Neopharm, Inc. Liposomal gemcitabine compositions for better drug delivery
EP1393720A1 (en) * 2002-08-27 2004-03-03 Universiteit Utrecht Vesicle-encapsulated corticosteroids for treatment of cancer
US7179645B2 (en) * 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
DE10249401A1 (de) * 2002-10-23 2004-05-13 Bernina Biosystems Gmbh Liposomen formende Zusammensetzung
US20050158375A1 (en) * 2002-11-15 2005-07-21 Toshikiro Kimura Pharmaceutical composition containing liposomes for treating cancer
WO2004052917A2 (en) * 2002-12-10 2004-06-24 Epimmune Inc. Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
ATE544772T1 (de) * 2002-12-23 2012-02-15 Dynavax Tech Corp Immunstimulierende sequenz-oligonukleotide und verwendungsverfahren dafür
US20050118154A1 (en) * 2003-04-02 2005-06-02 Mien-Chie Hung Antitumor effect of mutant Bik
ES2456666T3 (es) * 2003-04-18 2014-04-23 Biotech Synergy, Inc. Péptidos antígenos HLA-A2 asociados a un tumor y composiciones
AU2004267506A1 (en) * 2003-08-26 2005-03-03 Board Of Regents, The University Of Texas System Anti-cancer vaccines
US20050220781A1 (en) * 2003-09-04 2005-10-06 Duen-Hwa Yan IFIX, a novel HIN-200 protein, for cancer therapy
GB0321615D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
WO2005089164A2 (en) * 2003-12-31 2005-09-29 Pharmexa Inc. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
JP2007522119A (ja) * 2004-01-28 2007-08-09 キュリックス エーピーエス アミロイド関連疾患用ワクチンとしてのアミロイドタンパク質のコンジュゲート
ES2385492T3 (es) * 2004-04-02 2012-07-25 Board Of Regents, The University Of Texas System Promotores específicos de cáncer
ATE450251T1 (de) * 2004-05-17 2009-12-15 Tekmira Pharmaceuticals Corp Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy

Similar Documents

Publication Publication Date Title
Kersten et al. Liposomes and ISCOMS
Guan et al. Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses
Shariat et al. P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer
CN1096851C (zh) 疫苗组合物佐剂
US20210322573A1 (en) Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
CN101282742B (zh) 脂质体在含连续疏水相的载体中作为癌症治疗媒介物的应用
JP2014503475A5 (enExample)
Qiao et al. A MnAl double adjuvant nanovaccine to induce strong humoral and cellular immune responses
Nakamura et al. Incorporation of polyinosine–polycytidylic acid enhances cytotoxic T cell activity and antitumor effects by octaarginine-modified liposomes encapsulating antigen, but not by octaarginine-modified antigen complex
JP2022116265A (ja) 両親媒性化合物、新生抗原及び疎水性担体を含むワクチン組成物、並びにその使用方法
HRP20170433T1 (hr) Pripravci spoja za izmjenu lipidiranog imunološkog odgovora, formulacije, i postupci
Farzad et al. P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer
WO2016046060A1 (en) Stable formulations of lipids and liposomes
JP2013121977A5 (enExample)
JP7409594B2 (ja) 医薬組成物、規定のサイズの脂質ベシクル粒子を使用する調製物のための方法、及びそれらの使用
JP2013505201A5 (enExample)
JP2020506938A (ja) イミダゾキノリン系物質を含むナノエマルジョン及びその用途
Ahmad et al. Liposomes and niosomes for targeted drug and gene delivery systems
Du et al. MUC1 specific immune responses enhanced by coadministration of liposomal DDA/MPLA and lipoglycopeptide
Lin et al. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice
Barati et al. AE36 HER2/neu-derived peptide linked to positively charged liposomes with CpG-ODN as an effective therapeutic and prophylactic vaccine for breast cancer
JPH05504756A (ja) 免疫刺激性を有する組成物と、そのヒトと獣医学用医薬への応用
Kuai et al. Lipid-based nanoparticles for vaccine applications
Zamani et al. Improving potency of Nanoliposomal AE36 peptide vaccine by adding CD4+ T cell helper epitope and MPL in TUBO breast cancer mice model
Shariat et al. Preparation and characterization of different liposomal formulations containing P5 HER2/neu-derived peptide and evaluation of their immunological responses and antitumor effects